Tacrolimus plus ripertamab for first-time MCD treatment
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two medications (tacrolimus and ripertamab) as a first treatment for minimal change disease (MCD), a kidney condition that causes protein leakage. The goal is to see if this combo works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have minimal change disease, confirmed by kidney biopsy, and this is your first treatment.
- You must have very high protein in your urine (over 3.5 grams per day) and low albumin in your blood (below 30).
- You must not have been treated with steroids or other immune-suppressing drugs before.
- You must not have any serious health issues like heart disease, mental illness, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if obinutuzumab, a targeted therapy, can safely and effectively treat adults with their first episode of minimal change disease (MCD), a kidney condition causing protein leakage. Participants will receive the drug to see if it reduces protein in urine and improves symptoms.
This trial tests a new medicine called Ripertamab to see if it can help children and young adults with nephrotic syndrome who keep relapsing or need steroids to stay in remission. It aims to offer a treatment option that may reduce relapses.
This trial tests whether rituximab (an immune-targeting medicine) plus cyclosporine (another immune medicine) can better control protein leakage in the urine for people with idiopathic membranous nephropathy. It may help reduce long-lasting kidney damage risk when standard treatments like ACE inhibitor or ARB don’t control the protein level.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This Phase 3 trial compares different immune-suppressing medicines for idiopathic membranous nephropathy (a kidney disease caused by the immune system). It may help reduce heavy protein leakage in the urine and improve disease control in people who fit specific prior-treatment and lab requirements.
This study tests a drug called telitacicept for people with a kidney condition called membranous nephropathy. It aims to see if the drug is safe and helps reduce protein in urine, protecting kidney function.
Hear when a new Minimal Change Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.